Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

Scale for the Assessment of Negative Symptoms

1982 • 1,883 citations

Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine

1992 • 1,420 citations

Risperidone in the treatment of schizophrenia

1994 • 1,205 citations

A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients

1993 • 884 citations

Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs

1988 • 692 citations

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients

1993 • 529 citations

Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

1988 • 429 citations

Biochemical profile of risperidone, a new antipsychotic.

1988 • 393 citations

[sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease

1996 • 363 citations

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

1995 • 341 citations

Positron emission tomographic imaging of the dopamine transporter with ¹¹C‐WIN 35,428 reveals marked declines in mild Parkinson's disease

1993 • 319 citations

Tourette Syndrome: Prediction of Phenotypic Variation in Monozygotic Twins by Caudate Nucleus D2 Receptor Binding

1996 • 250 citations

The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study

1995 • 237 citations

Neuroleptics : neurochemical, behavioral, and clinical perspectives

1983 • 230 citations

5-HT2 and D2 dopamine receptor occupancy in the living human brain

1993 • 228 citations

Risperidone: clinical safety and efficacy in schizophrenia.

1992 • 208 citations

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

1992 • 207 citations

D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate

1995 • 148 citations

Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients

1989 • 120 citations

Neuropathology of Parkinson’s Disease and Related Syndromes

1992 • 101 citations

The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64 766) in the treatment of chronic psychosis

1989 • 96 citations

The Psychiatric Symptom Assessment Scale (PSAS).

1989 • 91 citations

Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects.

1994 • 90 citations

Individual variation in D2 dopamine receptor occupancy in clozapine- treated patients

1996 • 58 citations

[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics

1996 • 57 citations

Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease.

1995 • 54 citations

Peracetic acid as a superior oxidant for preparation of [¹²³I]IBZM: A potential dopamine D‐2 receptor imaging agent

1989 • 38 citations

Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol

1988 • 36 citations

Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration.

1988 • 33 citations

Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics

1994 • 29 citations